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Abstract 
Mast cells (MCs) are metachromatic cells
that originate from multipotential hemopoietic
stem cells in the bone marrow. Two distinct
populations of MCs have been characterized:
mucosal MCs are tryptase-positive while mast
cells in skin contain tryptase and chymase. We
now show that a sub-population of MCs is
highly immunoreactive for thymosin β4, as
revealed by immunohistochemical analyses of
normal skin, normal colon mucosa and salivary
gland tumors. Four consecutive serial sections
from each case were immunostained for thy-
mosin β4 (Tβ4), chymase, tryptase and stained
for toluidine blue. In skin biopsies, MCs
showed a comparable immunoreactivity for
Tβ4, chymase and tryptase. In normal colon
mucosa the vast majority of  mucosal MCs
expressed a strong cytoplasmic immunoreac-
tivity for tryptase and for Tβ4, in the absence of
chymase reactivity. A robust expression of Tβ4
was detected in tumor-infiltrating and peritu-
moral mast cells in salivary gland tumors and
breast ductal infiltrating carcinomas. Tumor-
infiltrating MCs also showed a strong
immunoreactivity for chymase and tryptase. In
this paper, we first demonstrate that normal
dermal and mucosal mast cells exhibit strong
expression of thymosin β4, which could be con-
sidered a new marker for the identification of
mast cells in skin biopsies as well as in human
tumors. The possible relationship between the
degree of Tβ4 expression in tumor-infiltrating
mast cells and tumor behaviour warrants fur-
ther consideration in future investigations.
Introduction
Mast cells (MCs) are metachromatic cells
that originate from multipotential hemopoietic
stem cells in the bone marrow, and reside in
vascularized tissues where they play an impor-
tant role in the innate immune system.1 The
developmental pathways of mast cells within
different tissues appear to be different.2,3 The
observation of two distinct populations of mast
cells, i.e. mucosal mast cells characterized by
reactivity for chondroitin sulfate E proteogly-
can4 and serosal or connective tissue-type
mast cells, characterized by the ability to
sinthesize heparin5 led to the concept of mast
cell heterogeneity. Heterogeneity of mast cells
has been reported in different tissues both in
animals6 and in men.7 It has been demonstrat-
ed that mucosal mast cells differ from skin and
peritoneal mast cells, even in the expression of
two classes of proteases, one with trypsin-like
activity, called tryptase,8 and one with a chi-
motrypsin-like activity, called chymase,9 which
are among the major components of mast cell
granules. In humans, these proteinases are
differentially expressed in mast cell subtypes:
mucosal MC are tryptase-positive, while mast
cells in skin contain tryptase and chymase.10
These MCs subtypes are designated MCt and
MCtc, respectively.  The specialization of mast
cells in different tissue sites has been hypoth-
esized to be related to their involvement in
physiology and pathology, which is yet poorly
understood.11 MCs can also be stained with
antibodies against c-kit.12 Histochemically,
mast cells may be easily revealed by toluidine
blue13 and by alcian blue-safranin14 stains. The
latter method is able to detect a higher number
of mast cells than toluidine blue staining.15
The fixation mode of tissue samples also influ-
ences the number of detected mast cells. It is
commonly accepted that Carnoy’s solution has
the best capacity to fix mast cell granules;16 for-
malin is also good and allows appropriate his-
tochemistry and immunohistochemistry for
MCs. The aim of this study is to propose the
introduction of thymosin β4 (Tβ4) as a new
marker for serosal, mucosal and tumor infil-
trating mast cells.
Materials and Methods
In order to test Tβ4 immunoreactivity in the
different subtypes of human MCs, we exam-
ined 10 surgical specimens of normal skin con-
taining tryptase and chymase-positive serosal
MCs and 10 normal colon biopsies containing
tryptase-positive mucosal mast cells. Tβ4
expression in tumor-infiltrating MCs was eval-
uated in 4 acinic cell carcinomas of salivary
glands and in 10 ductal infiltrating breast car-
cinomas. All 34 specimens were selected for
this study by the preliminary demonstration
through toluidine-blue stain of metachromatic
granules-containing MCs. Positive controls
included tonsil and reactive lymph nodes for
chymase and tryptase and for Tβ4, respectively.
All samples were fixed in 10% formalin, paraf-
fin-embedded and routinely processed. The
immunohistochemical technique was per-
formed in a DAKO autostainer. Paraffin sec-
tions from each case were immunostained
with the policlonal antibodies against thy-
mosin β4 (Bachem-Peninsula Lab, San Carlos,
CA, USA; diluted 1:500), chymase (Novocastra,
Benton Lane, Newcastle, UK clone CC1, dilut-
ed 1:200) and tryptase (Novocastra, Benton
Lane, Newcastle, UK clone 10D11, diluted
1:300). A LSAB2 system-HRP kit (DAKO) was
used and the signal was visualized by the AEC
(3-amino-9-ethylcarbazole) substrate. All sam-
ples were also stained with the toluidine-blue
method.
Results
In normal skin, dermal-serosal mast cells
showed substantially the same immunoreac-
tivity for chymase (Figure 1c) and tryptase
(Figure 1b). Moreover, the vast majority of
MCs showed reactivity for Tβ4 (Figure 1a).
Toluidin blue stain confirmed the same reac-
tivity pattern (data not shown). 
In normal colon mucosa, a different
immunoreactivity pattern was detected. The
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vast majority of mucosal MCs expressed a
strong cytoplasmic immunoreactivity for Tβ4
(Figure 2a), which paralleled the immunoreac-
tivity for tryptase (Figure 2b). Mucosal colonic
MCs did not show any significant reactivity for
chymase (Figure 2c). 
In salivary gland tumors, peri- and intratu-
moral MCs showed a comparable immunoreac-
tivity for tryptase (Figure 3b) and chymase
(Figure 3c). Immunoreactivity for Tβ4 was
found only in a subset of intratumoral mast
cells. (Figure 3a). 
In breast ductal infiltrating carcinomas,
tumor infiltrating and peritumoral MCs
showed a strong reactivity for  Tβ4 and
tryptase; immunoreactivity for chymase was
detected only in a subset of MCs. The same
pattern of reactivity was found in MCs sur-
rounding fibrocystic changes (Figure 4 a, b, c). 
Discussion
In this paper, we first demonstrate that nor-
mal dermal (serosal) and mucosal mast cells
exhibit strong expression of thymosin β4. Tβ4
expression was also found in tumor-infiltrat-
ing and peritumoral mast cells in salivary
gland and in breast tumors. These observa-
tions extend the knowledge regarding the
immunophenotypic profile of mast cells and
provide a useful new marker for the identifica-
tion of scattered mast cells in skin, colon
mucosa as well as in tumors. The co-expres-
sion or separate expression of chymase and
tryptase is currently used as a specific
immunophenotypic profile to distinguish and
characterize, on tissue sections,  different sub-
types of mast cells.10 According to our results,
Tβ4 could be considered as a marker for MCs in
this context, showing a degree of immunoreac-
tivity comparable in sensitivity to chymase and
tryptase. In this study Tβ4 demonstrated to
stain both serosal and mucosal MCs, parallel-
ing the sensitivity of tryptase in revealing tis-
sue MCs.
In addition, in this study we found a pattern
of reactivity for Tβ4 which could be useful to
better characterize, on tissue sections, a new
subtype of  tumor infiltrating and peritumoral
MCs. In salivary gland tumors, Tβ4 was detect-
ed only in a part of tumoral MCs, while reactiv-
ity for chymase and tryptase was found in all
MCs. A different protein reactivity pattern for
Tβ4 was found in intra- and peri-tumoral MCs
in infiltrating ductal carcinoma of the breast.
In this contest, MCs showed the highest level
of reactivity for Tβ4 and tryptase, whereas only
a minority of MCs were positive for chymase.
All together, these findings show a previously
unreported heterogeneity of tumor infiltrating
MCs, and introduce Tβ4 as a useful marker, in
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Figure 2. Normal colon mucosa:  original
magnification x400. (a) Immunohistochemi-
cal detection of Tβ4: the vast majority of
mucosal mast cells show a strong cytoplasmic
immunoreactivity. (b) Immunohistochemical
detection of tryptase shows cytoplasmic reac-
tivity in a minority of mucosal mast cells. (c)
Immunohistochemical detection of chymase
shows cytoplasmic reactivity in isolated
mucosal mast cells.
Figure 3. Acinic cell tumor of salivary gland:
original magnification x400. (a) Immuno-his-
tochemical detection of Tβ4 shows an intense
cytoplasmic immunoreactivity in a minority
of intratumoral mast cells. (b) Immunohi-
stochemical detection of tryptase shows cyto-
plasmic immunoreactivity in intratumoral
mast cells. (c) Mast cells’ immunoreactivity for
chymase shows an immunoreactive pattern
comparable to that obtained with tryptase.
Figure 1. Normal skin. Original magnifica-
tion x 250. (a) Immunohistochemical
detection of Tβ4 shows cytoplasmic reactiv-
ity in scattered dermal mast cells. (b)
Immunohistochemical detection of
tryptase shows intense cytoplasmic immu-
oreactivity restricted to mast cells. (c) Mast
cells’ immunoreactivity for chymase shows
an immunoreactive pattern comparable to
that obtained with tryptase. 
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association with  chymase and tryptase for the
identification of new subtypes of MCs. 
As far as the role of mast cells inside and
around malignant neoplasms is concerned, the
demonstration of strong Tβ4 expression in
intratumoral MCs can contribute to explain
their function as effectors of the innate
immune systems in the surveillance of tumor
progression. A number of experimental, bio-
chemical and microarray studies have already
documented the presence of a high level of
expression of Tβ4 in experimental and human
tumors.17,18 In particular, the role of Tβ4 has
been analyzed in relation to tumor metasta-
sis,19-21 in human lung cancer,22 and  in human
colorectal cancer.23 Recently, an immunohisto-
chemical study on Tβ4 expression in human
breast cancer revealed a low reactivity for the
peptide in cancer cells, while intense reactivi-
ty for Tβ4 was detected in other cells of the
tumor microenvironment.24 On the basis of our
data, we may hypothesize that Tβ4 - positive
peritumoral cells observed in that study could
be identified as MCs.
These data taken together, one may pose the
question whether the levels of Tβ4 recorded in
extracts of tumor samples in previous studies
reflected levels in tumor cells or in the tumour
microenvironment. Our data give an answer to
this question, and clearly indicate mast cells as
partly responsible for the connection between
Tβ4 and tumour progression.  The finding of a
strong reactivity for Tβ4 in tumour-infiltrating
mast cells lays stress on the hypothesis that
Tβ4 may constitute a local paracrine mediator
which could be relevant to our understanding
of cellular cross-talk within the tumor micro-
environment.24 Tβ4 has been shown to exert
anti-inflammatory and cytoprotective func-
tions, by suppressing secretion of the pro-
inflammatory cytokine, IL8 and by protecting
cells against apoptosis induced by tumor
necrosis factor-a.25 Moreover, in a murine
corneal model, Tβ4 potently inhibited neu-
trophil infiltration and significantly decreased
the expression of pro-inflammatory cyto-
kines.26 These data taken together, we may
speculate that, because of its multifunctional
roles in protecting cells against apoptosis25 and
in stimulating neoangiogenesis,27-29 Tβ4
released by mast cells in the tumor microenvi-
ronment could significantly contribute to can-
cer cell survival. As a consequence, Tβ4-pro-
ducing MCs could represent a new molecular
target for antitumoral strategies30 in different
human tumors.
Finally, the expression of Tβ4 in the cyto-
plasm of tumor-infiltrating mast cells reported
in this study extends our knowledge regarding
the immunophenotypic profile of mast cells
and can significantly contribute to our under-
standing of cross-talk between cells of the
immune system and tumour cells. The possible
relationship between the degree of mast cell
infiltration and tumor behaviour warrants fur-
ther consideration in future investigations.
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